BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025.
The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. | ||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||
Dollars in millions, except per share data | March 31, | December 31, | March 31, | Change | ||||||||||||||||
2025 | 2024 | 2024 | Prior Qtr | Prior Yr. | ||||||||||||||||
Revenue from Continuing Operations | $ | 143 | $ | 148 | $ | 136 | (3) | % | 5 | % | ||||||||||
Organic growth | 6 | % | ||||||||||||||||||
Sample Management Solutions | $ | 80 | $ | 81 | $ | 74 | (2) | % | 8 | % | ||||||||||
Multiomics | $ | 64 | $ | 66 | $ | 62 | (4) | % | 2 | % | ||||||||||
Diluted EPS Continuing Operations | $ | (0.40) | $ | (0.21) | $ | (0.29) | (93) | % | (36) | % | ||||||||||
Diluted EPS Total | $ | (0.88) | $ | (0.29) | $ | (2.47) | NM | 64 | % | |||||||||||
Non-GAAP Diluted EPS Continuing Operations | $ | 0.05 | $ | 0.08 | $ | 0.06 | (43) | % | (23) | % | ||||||||||
Adjusted EBITDA - Continuing Operations | $ | 14 | $ | 13 | $ | 8 | 7 | % | 75 | % | ||||||||||
Adjusted EBITDA Margin - Continuing Operations | 10.0 | % | 9.0 | % | 6.0 | % | ||||||||||||||
Management Comments
"We delivered another quarter of strong performance in an evolving and uncertain macroeconomic environment. Our performance in the second quarter and first half of our fiscal year demonstrates the resilience of our portfolio and the dedication of our teams that focus on our customers with our clearly differentiated products and services," said John Marotta, President and CEO. "We have a healthy balance sheet, and strong cash position, which provides optionality to continue investing in our long-term growth plans while maintaining our continued disciplined in capital deployment. We remain confident in our positioning and disciplined in how we operate the business while navigating these uncertain times."
Second Quarter Fiscal 2025 Results - Continuing Operations
Summary of GAAP Earnings Results - Continuing Operations
Summary of Non-GAAP Earnings Results - Continuing Operations
Cash and Liquidity as of March 31, 2025
Guidance for Continuing Operations for Full Year Fiscal 2025
Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges that are not representative of the normal operations of the business.
Conference Call and Webcast
Azenta management will webcast its second quarter fiscal 2025 earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.
The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay.
Regulation G – Use of Non-GAAP financial Measures
The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts.
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US, our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstance on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.
AZENTA INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.
AZENTA, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(unaudited) | ||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
March 31, | March 31, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenue | ||||||||||||||||
Products | $ | 41,955 | $ | 38,772 | $ | 85,782 | $ | 82,479 | ||||||||
Services | 101,463 | 97,583 | 205,146 | 195,601 | ||||||||||||
Total revenue | 143,418 | 136,355 | 290,928 | 278,080 | ||||||||||||
Cost of revenue | ||||||||||||||||
Products | 23,159 | 24,015 | 48,493 | 50,798 | ||||||||||||
Services | 54,373 | 51,676 | 107,878 | 104,875 | ||||||||||||
Total cost of revenue | 77,532 | 75,691 | 156,371 | 155,673 | ||||||||||||
Gross profit | 65,886 | 60,664 | 134,557 | 122,407 | ||||||||||||
Operating expenses | ||||||||||||||||
Research and development | 6,869 | 7,733 | 13,249 | 15,046 | ||||||||||||
Selling, general and administrative | 71,588 | 69,058 | 144,801 | 138,947 | ||||||||||||
Impairment of intangible assets | — | 4,658 | — | 4,658 | ||||||||||||
Restructuring charges | 3,580 | 3,428 | 4,011 | 4,214 | ||||||||||||
Total operating expenses | 82,037 | 84,877 | 162,061 | 162,865 | ||||||||||||
Operating loss | (16,151) | (24,213) | (27,504) | (40,458) | ||||||||||||
Other income | ||||||||||||||||
Interest income, net | 4,489 | 9,479 | 8,787 | 19,434 | ||||||||||||
Other income (expense), net | 1,157 | (268) | 2,360 | 250 | ||||||||||||
Loss before income taxes | (10,505) | (15,002) | (16,357) | (20,774) | ||||||||||||
Income tax expense | 7,680 | 1,200 | 11,249 | 2,620 | ||||||||||||
Loss from continuing operations | (18,185) | (16,202) | (27,606) | (23,394) | ||||||||||||
Loss from discontinued operations, net of tax | (22,271) | (120,678) | (26,190) | (129,210) | ||||||||||||
Net loss | $ | (40,456) | $ | (136,880) | $ | (53,796) | $ | (152,604) | ||||||||
Basic net loss per share: | ||||||||||||||||
Loss from continuing operations | $ | (0.40) | $ | (0.29) | $ | (0.60) | $ | (0.42) | ||||||||
Loss from discontinued operations, net of tax | (0.49) | (2.18) | (0.57) | (2.30) | ||||||||||||
Basic net loss per share | $ | (0.88) | $ | (2.47) | $ | (1.18) | $ | (2.72) | ||||||||
Diluted net loss per share: | ||||||||||||||||
Loss from continuing operations | $ | (0.40) | $ | (0.29) | $ | (0.60) | $ | (0.42) | ||||||||
Loss from discontinued operations, net of tax | (0.49) | (2.18) | (0.57) | (2.30) | ||||||||||||
Diluted net loss per share | $ | (0.88) | $ | (2.47) | $ | (1.18) | $ | (2.72) | ||||||||
Weighted average shares used in computing net loss per share: | ||||||||||||||||
Basic | 45,732 | 55,440 | 45,658 | 56,078 | ||||||||||||
Diluted | 45,732 | 55,440 | 45,658 | 56,078 | ||||||||||||
AZENTA, INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(unaudited) | ||||||||
(In thousands, except share and per share data) | ||||||||
March 31, | September 30, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 253,642 | $ | 280,030 | ||||
Short-term marketable securities | 74,697 | 151,162 | ||||||
Accounts receivable, net of allowance for expected credit losses ($5,624 and $5,349, respectively) | 149,490 | 156,273 | ||||||
Inventories | 83,321 | 78,923 | ||||||
Short-term restricted cash | 2,102 | 2,069 | ||||||
Prepaid expenses and other current assets | 67,590 | 75,456 | ||||||
Current assets held for sale | 79,754 | 88,894 | ||||||
Total current assets | 710,596 | 832,807 | ||||||
Property, plant and equipment, net | 151,716 | 155,622 | ||||||
Long-term marketable securities | 176,781 | 49,454 | ||||||
Long-term deferred tax assets | 731 | 837 | ||||||
Operating lease right-of-use assets | 59,856 | 60,406 | ||||||
Goodwill | 682,955 | 691,409 | ||||||
Intangible assets, net | 111,202 | 125,042 | ||||||
Other assets | 7,125 | 10,670 | ||||||
Noncurrent assets held for sale | 140,963 | 173,794 | ||||||
Total assets | $ | 2,041,925 | $ | 2,100,041 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 39,155 | $ | 33,344 | ||||
Deferred revenue | 41,608 | 30,493 | ||||||
Accrued warranty and retrofit costs | 5,237 | 5,213 | ||||||
Accrued compensation and benefits | 26,039 | 27,785 | ||||||
Accrued customer deposits | 26,318 | 22,324 | ||||||
Accrued income taxes payable | 10,321 | 9,266 | ||||||
Accrued expenses and other current liabilities | 43,102 | 46,364 | ||||||
Current liabilities held for sale | 28,933 | 30,050 | ||||||
Total current liabilities | 220,713 | 204,839 | ||||||
Long-term tax reserves | 417 | 398 | ||||||
Long-term deferred tax liabilities | 22,458 | 18,084 | ||||||
Long-term operating lease liabilities | 53,696 | 56,683 | ||||||
Other long-term liabilities | 10,062 | 8,874 | ||||||
Noncurrent liabilities held for sale | 33,087 | 42,196 | ||||||
Total liabilities | 340,433 | 331,074 | ||||||
Stockholders' equity | ||||||||
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding | — | — | ||||||
Common stock, $0.01 par value - 125,000,000 shares authorized, 59,237,887 shares issued and 45,776,018 shares outstanding at March 31, 2025; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024 | 593 | 590 | ||||||
Additional paid-in capital | 520,961 | 505,958 | ||||||
Accumulated other comprehensive loss | (42,149) | (13,464) | ||||||
Treasury stock, at cost - 13,461,869 shares at March 31, 2025 and September 30, 2024 | (200,956) | (200,956) | ||||||
Retained earnings | 1,423,043 | 1,476,839 | ||||||
Total stockholders' equity | 1,701,492 | 1,768,967 | ||||||
Total liabilities and stockholders' equity | $ | 2,041,925 | $ | 2,100,041 | ||||
AZENTA, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(unaudited) | ||||||||
(In thousands) | ||||||||
Six Months Ended March 31, | ||||||||
2025 | 2024 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (53,796) | $ | (152,604) | ||||
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 32,053 | 44,214 | ||||||
Impairment of goodwill and intangible assets | — | 115,975 | ||||||
Loss on assets held for sale | 24,187 | — | ||||||
Inventory write-downs and other asset write-offs | 4,326 | 7,499 | ||||||
Stock-based compensation | 13,453 | 8,804 | ||||||
Amortization and accretion on marketable securities | (983) | (2,084) | ||||||
Deferred income taxes | (1,885) | (9,456) | ||||||
(Gain) loss on disposals of property, plant and equipment | (7) | 260 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 6,713 | 2,922 | ||||||
Inventories | (6,030) | 8,238 | ||||||
Accounts payable | 1,864 | 936 | ||||||
Deferred revenue | 12,042 | 3,379 | ||||||
Accrued warranty and retrofit costs | 343 | (714) | ||||||
Accrued compensation and tax withholdings | (2,379) | (7,831) | ||||||
Accrued restructuring costs | 1,548 | 1,454 | ||||||
Other assets and liabilities | 12,752 | 1,379 | ||||||
Net cash provided by operating activities | 44,201 | 22,371 | ||||||
Cash flows from investing activities | ||||||||
Purchases of property, plant and equipment | (15,158) | (19,542) | ||||||
Purchases of marketable securities | (236,237) | (345,447) | ||||||
Sales and maturities of marketable securities | 184,636 | 190,504 | ||||||
Proceeds from other investment | 2,130 | — | ||||||
Net investment hedge settlement | 3,043 | 1,476 | ||||||
Net cash used in investing activities | (61,586) | (173,009) | ||||||
Cash flows from financing activities | ||||||||
Proceeds from issuance of common stock | 1,553 | 1,678 | ||||||
Payments of finance leases | (457) | (386) | ||||||
Share repurchases | — | (186,834) | ||||||
Excise tax payment for settled share repurchases | (11,376) | — | ||||||
Net cash used in financing activities | (10,280) | (185,542) | ||||||
Effects of exchange rate changes on cash, cash equivalents and restricted cash | (4,459) | 16,255 | ||||||
Net decrease in cash, cash equivalents and restricted cash | (32,124) | (319,925) | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 320,990 | 684,045 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 288,866 | $ | 364,120 | ||||
Supplemental disclosures: | ||||||||
Cash (received) / paid for income taxes, net | (4,594) | 5,008 | ||||||
Purchases of property, plant and equipment included in accounts payable and accrued expenses | 5,773 | 2,270 | ||||||
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets | ||||||||
March 31, | September 30, | |||||||
2025 | 2024 | |||||||
Cash and cash equivalents of continuing operations | $ | 253,642 | $ | 280,030 | ||||
Cash included in current assets held for sale | 27,025 | 30,899 | ||||||
Short-term restricted cash | 2,102 | 2,069 | ||||||
Long-term restricted cash included in other assets | 6,097 | 7,992 | ||||||
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows | $ | 288,866 | $ | 320,990 | ||||
Notes on Non-GAAP Financial Measures - Continuing Operations
Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.
Quarter Ended | ||||||||||||||||||||||||
March 31, 2025 | December 31, 2024 | March 31, 2024 | ||||||||||||||||||||||
per diluted | per diluted | per diluted | ||||||||||||||||||||||
Amounts in thousands, except per share data | $ | share | $ | share | $ | share | ||||||||||||||||||
Net loss from continuing operations | $ | (18,185) | $ | (0.40) | $ | (9,421) | $ | (0.21) | $ | (16,202) | $ | (0.29) | ||||||||||||
Adjustments: | ||||||||||||||||||||||||
Amortization of completed technology | 2,308 | 0.05 | 1,500 | 0.03 | 2,067 | 0.04 | ||||||||||||||||||
Amortization of other intangible assets | 3,803 | 0.08 | 4,573 | 0.10 | 5,152 | 0.09 | ||||||||||||||||||
Transformation costs(1) | 5,183 | 0.11 | 3,046 | 0.07 | 4,095 | 0.07 | ||||||||||||||||||
Restructuring charges | 3,580 | 0.08 | 431 | 0.01 | 3,428 | 0.06 | ||||||||||||||||||
Impairment of intangible assets | — | — | — | — | 4,658 | 0.08 | ||||||||||||||||||
Merger and acquisition costs and costs related to share repurchase(2) | 688 | 0.02 | 1,570 | 0.03 | 426 | 0.01 | ||||||||||||||||||
Investment income(3) | (2,130) | (0.05) | — | — | — | — | ||||||||||||||||||
Tax adjustments(4) | 6,900 | 0.15 | 408 | 0.01 | 1,645 | 0.03 | ||||||||||||||||||
Tax effect of adjustments | (40) | (0.00) | 1,530 | 0.03 | (1,959) | (0.04) | ||||||||||||||||||
Non-GAAP adjusted net income from continuing operations | $ | 2,107 | $ | 0.05 | $ | 3,637 | $ | 0.08 | $ | 3,310 | $ | 0.06 | ||||||||||||
Stock-based compensation, pre-tax | 8,031 | 0.18 | 4,872 | 0.11 | 5,410 | 0.10 | ||||||||||||||||||
Tax rate | 17 | % | — | 15 | % | — | 12 | % | — | |||||||||||||||
Stock-based compensation, net of tax | 6,690 | 0.15 | 4,141 | 0.09 | 4,761 | 0.09 | ||||||||||||||||||
Non-GAAP adjusted net income excluding stock-based compensation - continuing operations | $ | 8,797 | $ | 0.19 | $ | 7,778 | $ | 0.17 | $ | 8,071 | $ | 0.15 | ||||||||||||
Shares used in computing non-GAAP diluted net income per share | — | 45,732 | — | 45,626 | — | 55,440 | ||||||||||||||||||
Six Months Ended | ||||||||||||||||
March 31, 2025 | March 31, 2024 | |||||||||||||||
per diluted | per diluted | |||||||||||||||
Amounts in thousands, except per share data | $ | share | $ | share | ||||||||||||
Net loss from continuing operations | $ | (27,606) | $ | (0.60) | $ | (23,394) | $ | (0.42) | ||||||||
Adjustments: | ||||||||||||||||
Amortization of completed technology | 3,808 | 0.08 | 3,923 | 0.07 | ||||||||||||
Amortization of other intangible assets | 8,376 | 0.18 | 10,523 | 0.19 | ||||||||||||
Transformation costs(1) | 8,229 | 0.18 | 4,136 | 0.07 | ||||||||||||
Restructuring charges | 4,011 | 0.09 | 4,214 | 0.08 | ||||||||||||
Impairment of intangible assets | — | — | 4,658 | 0.08 | ||||||||||||
Merger and acquisition costs and costs related to share repurchase(2) | 2,258 | 0.05 | 4,747 | 0.08 | ||||||||||||
Investment income(3) | (2,130) | (0.05) | — | — | ||||||||||||
Tax adjustments(4) | 7,308 | 0.16 | 3,338 | 0.06 | ||||||||||||
Tax effect of adjustments | 1,490 | 0.03 | (4,288) | (0.08) | ||||||||||||
Non-GAAP adjusted net income from continuing operations | $ | 5,744 | $ | 0.13 | $ | 7,857 | $ | 0.14 | ||||||||
Stock-based compensation, pre-tax | 12,904 | 0.28 | 8,411 | 0.15 | ||||||||||||
Tax rate | 17 | % | — | 12 | % | — | ||||||||||
Stock-based compensation, net of tax | 10,749 | 0.24 | 7,402 | 0.13 | ||||||||||||
Non-GAAP adjusted net income excluding stock-based compensation - continuing operations | $ | 16,493 | $ | 0.36 | $ | 15,259 | $ | 0.27 | ||||||||
Shares used in computing non-GAAP diluted net income per share | — | 45,658 | — | 56,078 | ||||||||||||
(1) | Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. |
(2) | Includes expenses related to governance-related matters. |
(3) | The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature. |
(4) | Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Tax adjustments for the three and six months ended March 31, 2025 include $6.6 million of tax expenses related to a one-time repatriation of historical earnings from China. |
Quarter Ended | Six Months Ended | |||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | ||||||||||||||||
Dollars in thousands | 2025 | 2024 | 2024 | 2025 | 2024 | |||||||||||||||
GAAP net loss | $ | (40,456) | $ | (13,340) | $ | (136,880) | $ | (53,796) | $ | (152,604) | ||||||||||
Less: Loss from discontinued operations | (22,271) | (3,919) | (120,678) | (26,190) | (129,210) | |||||||||||||||
GAAP net loss from continuing operations | (18,185) | (9,421) | (16,202) | (27,606) | (23,394) | |||||||||||||||
Adjustments: | ||||||||||||||||||||
Interest income, net | (4,489) | (4,298) | (9,479) | (8,787) | (19,434) | |||||||||||||||
Income tax expense | 7,680 | 3,569 | 1,200 | 11,249 | 2,620 | |||||||||||||||
Depreciation | 7,818 | 7,474 | 7,395 | 15,292 | 14,815 | |||||||||||||||
Amortization of completed technology | 2,308 | 1,500 | 2,067 | 3,808 | 3,923 | |||||||||||||||
Amortization of other intangible assets | 3,803 | 4,573 | 5,152 | 8,376 | 10,523 | |||||||||||||||
Earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | (1,065) | $ | 3,397 | $ | (9,867) | $ | 2,332 | $ | (10,947) | ||||||||||
Quarter Ended | Six Months Ended | |||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | ||||||||||||||||
Dollars in thousands | 2025 | 2024 | 2024 | 2025 | 2024 | |||||||||||||||
Earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | (1,065) | $ | 3,397 | $ | (9,867) | $ | 2,332 | $ | (10,947) | ||||||||||
Adjustments: | ||||||||||||||||||||
Stock-based compensation | 8,031 | 4,872 | 5,410 | 12,904 | 8,411 | |||||||||||||||
Restructuring charges | 3,580 | 431 | 3,428 | 4,011 | 4,214 | |||||||||||||||
Impairment of intangible assets | — | — | 4,658 | — | 4,658 | |||||||||||||||
Merger and acquisition costs and costs related to share repurchase(1) | 688 | 1,570 | 426 | 2,258 | 4,747 | |||||||||||||||
Transformation costs(2) | 5,183 | 3,046 | 4,095 | 8,229 | 4,136 | |||||||||||||||
Investment income(3) | (2,130) | — | — | (2,130) | — | |||||||||||||||
Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | 14,287 | $ | 13,316 | $ | 8,150 | $ | 27,604 | $ | 15,219 | ||||||||||
(1) | Includes expenses related to governance-related matters. |
(2) | Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. |
(3) | The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature. |
Quarter Ended | ||||||||||||||||||||||||
Dollars in thousands | March 31, 2025 | December 31, 2024 | March 31, 2024 | |||||||||||||||||||||
GAAP gross profit | $ | 65,886 | 45.9 | % | $ | 68,671 | 46.6 | % | $ | 60,664 | 44.5 | % | ||||||||||||
Adjustments: | ||||||||||||||||||||||||
Amortization of completed technology | 2,308 | 1.6 | % | 1,500 | 1.0 | % | 2,067 | 1.5 | % | |||||||||||||||
Transformation costs(1) | — | — | % | 52 | 0.0 | % | 359 | 0.3 | % | |||||||||||||||
Other adjustments | (9) | (0.0) | % | 6 | 0.0 | % | — | — | % | |||||||||||||||
Non-GAAP adjusted gross profit | $ | 68,185 | 47.5 | % | $ | 70,229 | 47.6 | % | $ | 63,091 | 46.3 | % | ||||||||||||
Six Months Ended | ||||||||||||||||
Dollars in thousands | March 31, 2025 | March 31, 2024 | ||||||||||||||
GAAP gross profit | $ | 134,557 | 46.3 | % | $ | 122,407 | 44.0 | % | ||||||||
Adjustments: | ||||||||||||||||
Amortization of completed technology | 3,808 | 1.3 | % | 3,923 | 1.4 | % | ||||||||||
Transformation costs(1) | 52 | 0.0 | % | 359 | 0.1 | % | ||||||||||
Non-GAAP adjusted gross profit | $ | 138,417 | 47.6 | % | $ | 126,689 | 45.6 | % | ||||||||
(1) | Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. |
Sample Management Solutions | Multiomics | |||||||||||||||||||||||||||||||||||||||||||||||
Quarter Ended | Quarter Ended | |||||||||||||||||||||||||||||||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | |||||||||||||||||||||||||||||||||||||||||||
Dollars in thousands | 2025 | 2024 | 2024 | 2025 | 2024 | 2024 | ||||||||||||||||||||||||||||||||||||||||||
GAAP gross profit | $ | 38,251 | 47.9 | % | $ | 38,114 | 46.9 | % | $ | 32,943 | 44.4 | % | $ | 27,635 | 43.5 | % | $ | 30,557 | 46.1 | % | $ | 27,721 | 44.6 | % | ||||||||||||||||||||||||
Adjustments: | ||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of completed technology | 1,449 | 1.8 | % | 639 | 0.8 | % | 1,028 | 1.4 | % | 859 | 1.4 | % | 861 | 1.3 | % | 1,040 | 1.7 | % | ||||||||||||||||||||||||||||||
Transformation costs(1) | — | — | % | 52 | 0.1 | % | 359 | 0.5 | % | — | — | % | — | — | % | — | — | % | ||||||||||||||||||||||||||||||
Other adjustment | (9) | (0.0) | % | 5 | 0.0 | % | — | — | % | — | — | % | 1 | — | % | — | — | % | ||||||||||||||||||||||||||||||
Non-GAAP adjusted gross profit | $ | 39,691 | 49.7 | % | $ | 38,810 | 47.8 | % | $ | 34,330 | 46.3 | % | $ | 28,494 | 44.9 | % | $ | 31,419 | 47.4 | % | $ | 28,761 | 46.2 | % | ||||||||||||||||||||||||
Segment Total | ||||||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||||||
March 31, | December 31, | March 31, | ||||||||||||||||||||||
Dollars in thousands | 2025 | 2024 | 2024 | |||||||||||||||||||||
GAAP gross profit | $ | 65,886 | 45.9 | % | $ | 68,671 | 46.6 | % | $ | 60,664 | 44.5 | % | ||||||||||||
Adjustments: | ||||||||||||||||||||||||
Amortization of completed technology | 2,308 | 1.6 | % | 1,500 | 1.0 | % | 2,068 | 1.5 | % | |||||||||||||||
Transformation costs(1) | — | — | % | 52 | 0.0 | % | 359 | 0.3 | % | |||||||||||||||
Other adjustment | (9) | (0.0) | % | 6 | 0.0 | % | — | — | % | |||||||||||||||
Non-GAAP adjusted gross profit | $ | 68,185 | 47.5 | % | $ | 70,229 | 47.6 | % | $ | 63,091 | 46.3 | % | ||||||||||||
Sample Management Solutions | Multiomics | |||||||||||||||||||||||||||||||
Six Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||
Dollars in thousands | March 31, 2025 | March 31, 2024 | March 31, 2025 | March 31, 2024 | ||||||||||||||||||||||||||||
GAAP gross profit | $ | 76,366 | 47.4 | % | $ | 66,215 | 43.2 | % | $ | 58,191 | 44.8 | % | $ | 56,192 | 45.0 | % | ||||||||||||||||
Adjustments: | ||||||||||||||||||||||||||||||||
Amortization of completed technology | 2,088 | 1.3 | % | 1,843 | 1.4 | % | 1,720 | 1.3 | % | 2,080 | 1.7 | % | ||||||||||||||||||||
Transformation costs(1) | 52 | 0.0 | % | 359 | 0.3 | % | — | — | % | — | — | % | ||||||||||||||||||||
Non-GAAP adjusted gross profit | $ | 78,506 | 48.7 | % | $ | 68,417 | 44.7 | % | $ | 59,911 | 46.2 | % | $ | 58,272 | 46.6 | % | ||||||||||||||||
Segment Total | ||||||||||||||||
Six Months Ended | ||||||||||||||||
Dollars in thousands | March 31, 2025 | March 31, 2024 | ||||||||||||||
GAAP gross profit | $ | 134,557 | 46.3 | % | $ | 122,407 | 44.0 | % | ||||||||
Adjustments: | ||||||||||||||||
Amortization of completed technology | 3,808 | 1.3 | % | 3,923 | 1.4 | % | ||||||||||
Transformation costs(1) | 52 | 0.0 | % | 359 | 0.1 | % | ||||||||||
Non-GAAP adjusted gross profit | $ | 138,417 | 47.6 | % | $ | 126,689 | 45.6 | % | ||||||||
(1) | Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. |
Sample Management Solutions | Multiomics | |||||||||||||||||||||||
Quarter Ended | Quarter Ended | |||||||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | |||||||||||||||||||
Dollars in thousands | 2025 | 2024 | 2024 | 2025 | 2024 | 2024 | ||||||||||||||||||
GAAP operating income (loss) | $ | 567 | $ | 1,562 | $ | (2,894) | $ | (6,132) | $ | (3,387) | $ | (3,920) | ||||||||||||
Adjustments: | ||||||||||||||||||||||||
Amortization of completed technology | 1,449 | 639 | 1,028 | 859 | 861 | 1,040 | ||||||||||||||||||
Amortization of other intangible assets | — | 13 | 52 | — | — | — | ||||||||||||||||||
Transformation costs(1) | 2,606 | 103 | 359 | — | — | — | ||||||||||||||||||
Restructuring charges | — | — | — | (23) | 23 | — | ||||||||||||||||||
Other adjustments | (9) | — | (2) | — | — | — | ||||||||||||||||||
Non-GAAP adjusted operating income (loss) | $ | 4,613 | $ | 2,317 | $ | (1,457) | $ | (5,296) | $ | (2,503) | $ | (2,880) | ||||||||||||
Total Segments | Corporate | Total | ||||||||||||||||||||||||||||||||||
Quarter Ended | Quarter Ended | Quarter Ended | ||||||||||||||||||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | ||||||||||||||||||||||||||||
Dollars in thousands | 2025 | 2024 | 2024 | 2025 | 2024 | 2024 | 2025 | 2024 | 2024 | |||||||||||||||||||||||||||
GAAP operating income (loss) | $ | (5,565) | $ | (1,825) | $ | (6,814) | $ | (10,586) | $ | (9,528) | $ | (17,399) | $ | (16,151) | $ | (11,353) | $ | (24,213) | ||||||||||||||||||
Adjustments: | ||||||||||||||||||||||||||||||||||||
Amortization of completed technology | 2,308 | 1,500 | 2,068 | — | — | (1) | 2,308 | 1,500 | 2,067 | |||||||||||||||||||||||||||
Amortization of other intangible assets | — | 13 | 52 | 3,803 | 4,560 | 5,100 | 3,803 | 4,573 | 5,152 | |||||||||||||||||||||||||||
Transformation costs(1) | 2,606 | 103 | 359 | 2,577 | 2,943 | 3,736 | 5,183 | 3,046 | 4,095 | |||||||||||||||||||||||||||
Restructuring charges | (23) | 23 | — | 3,603 | 408 | 3,428 | 3,580 | 431 | 3,428 | |||||||||||||||||||||||||||
Impairment of intangible assets | — | — | — | — | — | 4,658 | — | — | 4,658 | |||||||||||||||||||||||||||
Merger and acquisition costs and costs related to share repurchase(2) | — | — | — | 688 | 1,570 | 426 | 688 | 1,570 | 426 | |||||||||||||||||||||||||||
Other adjustments | (9) | — | (2) | — | 9 | 2 | (9) | 9 | — | |||||||||||||||||||||||||||
Non-GAAP adjusted operating income (loss) | $ | (683) | $ | (186) | $ | (4,337) | $ | 85 | $ | (38) | $ | (50) | $ | (598) | $ | (224) | $ | (4,387) | ||||||||||||||||||
Sample Management Solutions | Multiomics | |||||||||||||||
Six Months Ended | Six Months Ended | |||||||||||||||
Dollars in thousands | March 31, | March 31, | March 31, | March 31, | ||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
GAAP operating income (loss) | $ | 2,129 | $ | (4,380) | $ | (9,519) | $ | (8,223) | ||||||||
Adjustments: | ||||||||||||||||
Amortization of completed technology | 2,088 | 1,843 | 1,720 | 2,080 | ||||||||||||
Amortization of other intangible assets | — | 103 | — | — | ||||||||||||
Transformation costs(1) | 2,709 | 359 | — | — | ||||||||||||
Other adjustments | 4 | 2 | 3 | (1) | ||||||||||||
Non-GAAP adjusted operating income (loss) | $ | 6,930 | $ | (2,073) | $ | (7,796) | $ | (6,144) | ||||||||
Total Segments | Corporate | Total | ||||||||||||||||||||||
Six Months Ended | Six Months Ended | Six Months Ended | ||||||||||||||||||||||
Dollars in thousands | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, | ||||||||||||||||||
2024 | 2024 | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
GAAP operating loss | $ | (7,390) | $ | (12,603) | $ | (20,114) | $ | (27,855) | $ | (27,504) | $ | (40,458) | ||||||||||||
Adjustments: | ||||||||||||||||||||||||
Amortization of completed technology | 3,808 | 3,923 | — | — | 3,808 | 3,923 | ||||||||||||||||||
Amortization of other intangible assets | — | 103 | 8,376 | 10,420 | 8,376 | 10,523 | ||||||||||||||||||
Transformation costs(1) | 2,709 | 359 | 5,520 | 3,777 | 8,229 | 4,136 | ||||||||||||||||||
Restructuring charges | — | — | 4,011 | 4,214 | 4,011 | 4,214 | ||||||||||||||||||
Impairment of intangible assets | — | — | — | 4,658 | — | 4,658 | ||||||||||||||||||
Merger and acquisition costs and costs related to share repurchase(2) | — | — | 2,258 | 4,747 | 2,258 | 4,747 | ||||||||||||||||||
Other adjustments | 7 | 1 | (7) | (2) | — | (1) | ||||||||||||||||||
Non-GAAP adjusted operating income (loss) | $ | (866) | $ | (8,217) | $ | 44 | $ | (41) | $ | (822) | $ | (8,258) | ||||||||||||
(1) | Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. |
(2) | Includes expenses related to governance-related matters. |
Sample Management Solutions | Multiomics | Azenta Total | ||||||||||||||||||||||||||||||||||
Quarter Ended | Quarter Ended | Quarter Ended | ||||||||||||||||||||||||||||||||||
March 31, | March 31, | March 31, | March 31, | March 31, | March 31, | |||||||||||||||||||||||||||||||
Dollars in millions | 2025 | 2024 | Change | 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||
Revenue | $ | 80 | $ | 74 | 8 | % | $ | 64 | $ | 62 | 2 | % | $ | 143 | $ | 136 | 5 | % | ||||||||||||||||||
Currency exchange rates | 0 | — | 1 | % | 1 | — | 1 | % | 1 | — | 1 | % | ||||||||||||||||||||||||
Organic revenue | $ | 80 | $ | 74 | 8 | % | $ | 64 | $ | 62 | 3 | % | $ | 144 | $ | 136 | 6 | % | ||||||||||||||||||
Sample Management Solutions | Multiomics | Azenta Total | ||||||||||||||||||||||||||||||||||
Six Months Ended | Six Months Ended | Six Months Ended | ||||||||||||||||||||||||||||||||||
March 31, | March 31, | March 31, | March 31, | March 31, | March 31, | |||||||||||||||||||||||||||||||
Dollars in millions | 2025 | 2024 | Change | 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||
Revenue | $ | 161 | $ | 153 | 5 | % | $ | 130 | $ | 125 | 4 | % | $291 | $ | 278 | 5 | % | |||||||||||||||||||
Currency exchange rates | 0 | — | 0 | % | 1 | — | 0 | % | 1 | — | 0 | % | ||||||||||||||||||||||||
Organic revenue | $ | 161 | $ | 153 | 5 | % | $ | 130 | $ | 125 | 4 | % | $ | 292 | $278 | 5 | % | |||||||||||||||||||
| Last Trade: | US$26.77 |
| Daily Change: | -0.94 -3.39 |
| Daily Volume: | 853,825 |
| Market Cap: | US$1.220B |
November 12, 2024 November 04, 2024 October 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
